You are viewing a shared deal. With a free account you access the full showcase and talk directly with whoever manages the deal.

Pre-IPO
Neuralink
Brain-computer interface company implanting devices in human trial participants.
Last published price (USD)$287.71
25 Aug 2026 — 3 Nov 2026+19.9%
25 Aug 202628 Oct 20263 Nov 2026
$287.71Last published price (USD)
$9.62BPost-money valuation
LimitedMarket activity
LiveStatus
Who they are & what they do
SectorHealthcare
Industries
Medical DevicesBrain-Computer InterfacesNeurotechnology
Company overview chevron_right
Neuralink, co-founded by Elon Musk, develops implantable brain-computer interfaces enabling people with paralysis to control devices by thought, currently in human trials.
Key investors
Ark InvestFounders FundSequoia CapitalThrive CapitalLightspeedQatar Investment AuthorityVy Capital
Founded 2016
Country
United States
United StatesWebsite neuralink.com
publicWebsite: neuralink.com
Why look at this deal
Highlights
- 01BCI Leader
- 02Human Trials
- 03Medtech Frontier
- 04Musk Ecosystem
- 05Long Horizon
Deal snapshot
Market activityLimited
Last published price (USD)$287.71
Last roundSeries E
Round dateJune 2025
Amount raised (last round)$650M
Post-money valuation$9.62B
Total funding$1.34B
LFR price/share$50.50
Pre-IPO investment risks
Standard notice applying to all pre-IPO deals. This platform only publishes information about the opportunity: each deal is managed by a regulated, licensed investment firm or bank in the relevant jurisdictions.
- Illiquidity. There is no regulated market: the ability to sell depends on secondary-market demand.
- Price not guaranteed. The last published price is not an official market price and can vary between transactions.
- Uncertain valuation. Based on private rounds and limited transactions, not on audited public financial statements.
- No IPO guarantee. The listing may be delayed or never happen; the liquidity horizon is undetermined.
- Lock-up. If the company lists, selling restrictions of 90–180 days or longer may apply.
- Limited information. Private companies have reduced disclosure obligations and not-always-audited data.
- Dilution. Subsequent rounds can dilute existing positions, even significantly.
- Transfer restrictions. Rights of first refusal (ROFR) and corporate consents can delay or prevent settlement.
Data room
Public files are open to everyone. The rest unlock once you qualify.
For companies and advisors
Have a deal to bring to market?
Publish your deal on UCapital Dealflow and reach qualified buyers and investors. Data room, NDA and lead management included.